These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12824806)

  • 1. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen.
    Bani-Sadr F; Fournier S; Molina JM
    AIDS; 2003 Jul; 17(10):1580-1. PubMed ID: 12824806
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
    Torre-Cisneros J; Pozo F; Serrano R; Vidal E; Rivero A; Tenorio A
    AIDS; 2000 Sep; 14(14):2215-7. PubMed ID: 11061671
    [No Abstract]   [Full Text] [Related]  

  • 3. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
    Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
    AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of a HAART regimen on the expression of HIV-associated Kaposi sarcoma.
    Paparizos VA; Kyriakis KP; Kourkounti S; Leuow K; Daskalakis E; Katsambas A
    J Acquir Immune Defic Syndr; 2008 Sep; 49(1):111. PubMed ID: 18725809
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?
    Ridolfo AL; Corbellino M; Tosca N; Capelletti A; Scalamogna C; Galli M; Parravicini C
    AIDS; 2004 May; 18(8):1224-6. PubMed ID: 15166546
    [No Abstract]   [Full Text] [Related]  

  • 8. HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?
    Philibert P; Chiche L; Caillères S; Allemand J; Rebaudet S; Delord M; Stavris C; Retornaz F; Khiri H; Halfon P
    AIDS; 2017 Sep; 31(15):2167-2169. PubMed ID: 28692546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
    Leitch H; Trudeau M; Routy JP
    HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy.
    Simonetti FR; Ricaboni D; Cattaneo D; Micheli V; Rusconi S; Gervasoni C
    J Clin Virol; 2016 Jan; 74():75-7. PubMed ID: 26682615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma.
    Tavio M; Nasti G; Spina M; Errante D; Vaccher E; Tirelli U
    Ann Oncol; 1998 Aug; 9(8):923. PubMed ID: 9789620
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy.
    Niehues T; Horneff G; Megahed M; Schroten H; Wahn V
    AIDS; 1999 Jun; 13(9):1148-9. PubMed ID: 10397553
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma.
    Stebbing J; Portsmouth S; Nelson M; Mandalia S; Kandil H; Alexander N; Davies L; Brock C; Bower M; Gazzard B
    Int J Cancer; 2004 Feb; 108(4):631-3. PubMed ID: 14696132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
    Shaw AJ; McLean KA
    Int J STD AIDS; 1999 Jun; 10(6):417-8. PubMed ID: 10414887
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma.
    Schwartz JD; Howard W; Scadden DT
    AIDS; 1999 Feb; 13(2):283-4. PubMed ID: 10202837
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
    Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F
    AIDS; 2002 Jan; 16(2):304-5. PubMed ID: 11807324
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.